Patient groups give Lundbeck top marks
H. Lundbeck A/S (Lundbeck) ranked at the very top of a new global survey carried out among 600 patient groups from 56 different countries. With an overall first place, Lundbeck moved up from its number three ranking from a similar survey in 2011, placing ahead of Novartis and Gilead Science.
Patient groups were asked to judge pharmaceutical companies on six parameters. In addition to taking the overall first place, Lundbeck also took top honours in two of the six parameters, “best at providing high-quality information to patients” and “best at being transparent with external stakeholders”